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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Slovene language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 100 JIA patients (7.0% systemic, 47.0% oligoarticular, 22.0% RF negative polyarthritis, 
24.0% other categories) and 120 healthy children, were enrolled. The JAMAR components discriminated well healthy subjects 
from JIA patients, except for the Health-Related Quality of Life, Psychosocial Health subscales. All JAMAR components 
revealed good psychometric performances. In conclusion, the Slovene version of the JAMAR is a valid tool for the assess-
ment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR
Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Slovene parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
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(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Slovene language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from July 2012 to 
December 2015. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10];
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle Visual Analogue Scale (VAS) 
[11];
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. Rating of the level of disease activity on a 21-circle 
VAS;
 7. Rating of disease status at the time of the visit (cat-
egorical scale);
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications;
 11. Report of difficulties with medication administration 
(list of items);
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. For the Slo-
vene version, cross cultural adaptation of the standard Eng-
lish version was performed. Reading, comprehension and 
understanding of the translated questionnaires were tested in 
a probe sample of 10 JIA parents and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
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assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Slovene parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Slovene JAMAR was fully cross-culturally adapted 
from the standard English version with 3 forward and 2 
backward translations with a concordance for 123/123 trans-
lations lines (100%) for the parent version and 119/120 lines 
(99.2%) for the child version.
All the 123 lines in the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median 100%; range 90–100%). All the 120 lines in the par-
ent version of the JAMAR were understood by at least 80% 
of the 10 children tested (median 100%; range 80–100%). 
The text of the parent and child JAMAR was unmodified 
after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 123 healthy children (total 
of 223 subjects), were enrolled at the paediatric rheumatol-
ogy centre. Three healthy children did not give the consent 
to use their data.
In the 100 JIA subjects, the JIA categories were 7% with 
systemic arthritis, 47% with oligoarthritis, 22% with RF 
negative polyarthritis, 2% with RF positive polyarthritis, 4% 
with psoriatic arthritis, 9% with enthesitis related arthritis 
and 9% with undifferentiated arthritis (Table 1).
A total of 217/220 (98.6%) subjects had the parent ver-
sion of the JAMAR completed by a parent (100 from parents 
of JIA patients and 117 from parents of healthy children). 
The JAMAR was completed by 182/217 (83.9%) mothers 
and 35/217 (16.1%) fathers. The child version of the JAMAR 
was completed by 130/220 (59.1%) children age 6.2 or older. 
Also patients younger than 7 years, capable to assess their 
personal condition and able to read and write, were asked to 
fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in psychosocial quality of life items.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items 
except for items 1, 6, 7, 8 and 10, whereas a reduced number 
of response choices were used for all the PF items except for 
items 1, 2, 3 and 4.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items (data 
not shown). The median number of items marked as not 
applicable was 0.0% (0–0%) for the PF and 2.5% (1–3.0%) 
for the HRQoL.
S366 Rheumatology International (2018) 38 (Suppl 1):S363–S369
1 3
Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 100 JIA patients
Data related to the JAMAR refers to the 100 JIA patients and to the 117 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS Visual Ana-
logue Scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function 
(total score ranges from 0 to 45), HRQoL Health-Related Quality of Life (total score ranges from 0 to 30), PhH physical Health (total score 
ranges from 0 to 15), PsH psychosocial Health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001 #p < 0.0001
Systemic Oligoarthritis RF− poly-
arthritis
RF+ poly-
arthritis
Psoriatic 
arthritis
Enthesitis 
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 7 N = 47 N = 22 N = 2 N = 4 N = 9 N = 9 N = 100 N = 120
Female 4 (57.1%) 39 (83%) 20 (90.9%) 2 (100%) 4 (100%) 1 (11.1%) 8 (88.9%) 78 (78%)** 58 (48.3%)#
Age at visit 7.5 (6.8–15.3) 8.5 (4.8–12.3) 9.7 (8.2–13.1) 11.3 (9–13.6) 14.9 (9–17.4) 15 (11.7–
16.3)
10.7 
(7.3–14.6)
9.5 (6.2–
13.7)*
9.9 (7.7–
12.9)
Age at onset 4.6 (3.7–6.3) 2.9 (1.9–6.1) 5.7 (2.9–7.5) 8.7 (5.8–11.7) 9.8 (5.7–12.6) 10.3 
(9.1–12.9)
7.3 (6.3–11.4) 4.8 (2.3–
8.7)**
Disease duration 3.6 (1.3–5.2) 3 (1.9–5.8) 4.6 (1.6–6.9) 2.6 (1.9–3.2) 3.2 (2.9–5.1) 2.5 (1.4-3) 3.4 (1.9–3.6) 3.2 (1.9–5.7)
ESR 4.5 (2.5–17.5) 7.5 (5–22) 9.5 (5–20) 20 (20–20) 18 (18–18) 9 (6–24) 8.5 (6–11) 8 (5–20)
MD VAS 
(0–10 cm)
0.5 (0–3) 0.5 (0–2) 0.8 (0–3) 0.5 (0–1) 0 (0–1) 0 (0–0.5) 1 (0.5–1.5) 0.5 (0–2)
No. swollen joints 0 (0–2) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0.5) 0 (0–0) 0 (0–1) 0 (0–1)
No. joints with 
pain
0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0)
No. joints with 
LOM
1 (0–2) 0 (0–1) 0 (0–1) 1 (0–2) 0 (0–1.5) 0 (0–1) 1 (0–2) 0 (0–1)
No. active joints 0 (0–2) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0.5) 0 (0–0) 0 (0–1) 0 (0–1)
Active systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ANA status 0 (0%) 10 (21.3%) 5 (22.7%) 1 (50%) 2 (50%) 0 (0%) 0 (0%) 18 (18%)
Uveitis 0 (0%) 5/46 (10.9%) 1 (4.5%) 0 (0%) 0 (0%) 0 (0%) 1 (11.1%) 7/99 (7.1%)
PF total score 0 (0–0) 0 (0–2) 1 (0–4) 2 (0–4) 2.5 (0–6.5) 0 (0–4) 0 (0–3) 0 (0–3) 0 (0–0)#
Pain VAS 0 (0–1) 0 (0–3) 0.5 (0–1.5) 2.8 (0–5.5) 1.3 (0–2.8) 2 (0.5–7) 1 (0–1.5) 0.5 (0–2.8) 0 (0–0)#
Disease activity 
VAS
0 (0–2) 1 (0–3) 1 (0.5–2) 0.5 (0–1) 0.3 (0–1.5) 4.5 (0–5) 1.5 (1–3.5) 1 (0–3)
Well-being VAS 0 (0–0) 0.5 (0–3) 0.5 (0–1) 0.5 (0–1) 1 (0.3–2.8) 0 (0–4) 1 (0–6) 0.5 (0–2)
HRQoL PhH 0 (0–2) 1 (0–3) 3 (1–4) 3.5 (0–7) 2.5 (1–4.5) 7 (1–8) 1 (1–7) 1 (0–4) 0 (0–1)#
HRQoL PsH 0 (0–0) 1 (0–3) 1 (0–3) 2 (0–4) 3 (0.5–5) 2 (0–7) 0 (0–6) 0.5 (0–4) 1 (0–3)
HRQoL total 
score
0 (0–2) 2 (0–5) 3 (1–7) 5.5 (0–11) 5.5 (2–9) 7 (3–17) 1 (1–15) 3 (0–7) 1 (0–3)**
Pain/swell. in > 1 
joint
2 (28.6%) 22 (46.8%) 8 (36.4%) 0 (0%) 1 (25%) 6 (66.7%) 7 (77.8%) 46 (46%) 7/117 (6%)#
Morning stiff-
ness > 15 min
0 (0%) 4 (8.5%) 0 (0%) 0 (0%) 0 (0%) 3 (33.3%) 1 (11.1%) 8 (8%) 2/117 
(1.7%)*
Subjective remis-
sion
3 (42.9%) 21 (44.7%) 8 (36.4%) 1 (50%) 2 (50%) 4 (44.4%) 5 (55.6%) 44 (44%)
In treatment 6 (85.7%) 32 (68.1%) 17 (77.3%) 2 (100%) 2 (50%) 7 (77.8%) 5 (55.6%) 71 (71%)
Reporting side 
effects
2/6 (33.3%) 8/32 (25%) 5/17 (29.4%) 0 (0%) 0 (0%) 0 (0%) 2/5 (40%) 17/71 
(23.9%)
Taking medication 
regularly
6/6 (100%) 32/32 (100%) 17/17 (100%) 2 (100%) 2/2 (100%) 7/7 (100%) 5/5 (100%) 71/71 (100%)
With problems 
attending school
0 (0%) 3/21 (14.3%) 0 (0%) 0 (0%) 1/3 (33.3%) 0 (0%) 1/5 (20%) 5/51 (9.8%) 0 (0%)*
Satisfied with dis-
ease outcome
7 (100%) 40 (85.1%) 21 (95.5%) 2 (100%) 4 (100%) 7 (77.8%) 7 (77.8%) 88 (88%)
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Floor and ceiling effect
The median floor effect was 92.0% (87.0–97.0%) for the PF 
items, 60.0% (47.0–72.0%) for the HRQoL PhH items, and 
66.0% (66.0–72.0%) for the HRQoL PsH items. The median 
ceiling effect was 0.0% (0.0–1.0%) for the PF items, 4.0% 
(3.0–7.0%) for the HRQoL PhH items, and 0.0% (0.0–0.0%) 
for the HRQoL PsH items. The median floor effect was 
47.0% for the pain VAS, 39.0% for the disease activity VAS 
and 48.0% for the well-being VAS. The median ceiling effect 
was 1.0% for the pain VAS, 3.0% for the disease activity 
VAS and 0% for the well-being VAS.
Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 86.7% of the 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL Health-Related Quality of Life, PhH physical Health, PsH psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent, N = 100/217 Child, N = 63/130
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 92.0% 90.5%
 HRQoL PhH 60.0% 71.4%
 HRQoL PsH 66.0% 69.8%
 Pain VAS 47.0% 36.5%
 Disease activity VAS 39.0% 36.5%
 Well-being VAS 48.0% 50.8%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 4.0% 1.6%
 HRQoL PsH 0.0% 0.0%
 Pain VAS 1.0% 0.0%
 Disease activity VAS 3.0% 1.6%
 Well-being VAS 0.0% 0.0%
Items with equivalent item-scale correlation 87% for PF, 90% for HRQoL 73% for PF, 90% for HRQoL
Items with items-scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 67% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.82 0.84
 PF-HW 0.74 0.89
 PF-US 0.64 0.47
 HRQoL-PhH 0.86 0.86
 HRQoL-PsH 0.85 0.76
Items with item-scale correlation lower than the Cronbach alpha 93% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.60 –
 HRQoL-PhH 0.62 –
 HRQoL-PsH 0.97 –
Spearman’s correlation with JIA core-set variables, median
 PF 0.4 0.4
 HRQoL PhH 0.4 0.4
 HRQoL PsH 0.3 0.2
 Pain VAS 0.2 0.3
 Disease activity VAS 0.3 0.4
 Well-being VAS 0.3 0.4
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PF items, with the exception of PF items 5 and 15, and for 
90% of the HRQoL items, with the exception of HRQoL 
item 1.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 86.7% of 
items of the PF (except for PF items 5 and 15) and 100% of 
items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.82 for PF-LL, 0.74 for PF-HW, 0.64 
for PF-US. Cronbach’s alpha was 0.86 for HRQoL-PhH and 
0.85 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha, with 
the exception of the PF item 3.
Test–retest reliability
Reliability was assessed in 3 JIA patients, by re-administer-
ing both versions (parent and child) of the JAMAR after a 
median of 10 days (0–25 days). The intraclass correlation 
coefficients (ICC) for the PF total score showed a substantial 
reproducibility (ICC = 0.60). The ICC for the HRQoL PhH 
showed a substantial reproducibility (ICC = 0.62) and for 
the HRQoL PsH showed an almost perfect reproducibility 
(ICC = 0.97).
Convergent validity
The Spearman’s correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.2 to 0.5 
(median = 0.4). The PF total score best correlation was 
observed with the parent assessment of pain and with the 
parent global assessment of well-being (r = 0.5, p < 0.001, 
for both). For the HRQoL, the median correlation of the PhH 
with the JIA core set of outcome variables ranged from 0.1 
to 0.7 (median = 0.4), whereas for the PsH ranged from 0.2 
to 0.5 (median = 0.3). The PhH showed the best correlation 
with the parent’s assessment of pain (r = 0.7, p < 0.001) and 
the PsH with the parent global assessment of well-being 
(r = 0.6, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centered and laboratory measures were 0.2 
(0.1–0.4), 0.3 (0.2–0.4), 0.3 (0.2–0.4), respectively.
Discussion
In this study, the Slovene version of the JAMAR was cross-
culturally adapted from the original standard English version 
with three forward and two backward translations. Accord-
ing to the results of the validation analysis, the Slovene par-
ent and patient versions of the JAMAR possess satisfactory 
psychometric properties. The disease-specific components 
of the questionnaire discriminated well between patients 
with JIA and healthy controls. Notably, there was no sig-
nificant difference between the healthy subjects and their 
affected peers in the psychosocial quality of life. This find-
ing indicates that children with JIA adapt well to the con-
sequences of JIA. Psychometric evaluation was good for all 
domains with few exceptions: PF item 5 (“bend down to pick 
up an object off the floor”) and item 15 (“bite a sandwich 
or an apple”) showing a lower Items internal consistency. 
However, the overall internal consistency was good for all 
the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
Notably, it was not possible to calculate the ICC for the PF 
total score, for the HRQoL PhH and for the HRQoL PsH 
since only one children retest was available for the analysis.
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care. In conclusion, the Slo-
vene version of the JAMAR was found to have satisfactory 
psychometric properties and it is, thus, a reliable and valid 
tool for the multidimensional assessment of children with 
JIA.
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